EnteroBiotix: EnteroBiotix reports positive results from TrIuMPH phase 2a trial of EBX10202 in adults with irritable bowel syndrome with constipation

EnteroBiotix: EnteroBiotix completes patient recruitment in phase 2 TrIuMPH study of EBX10202 in irritable bowel syndrome

EnteroBiotix: EnteroBiotix reports positive results from phase 1b IMPuLCE study of EBX102 in liver cirrhosis

EnteroBiotix: EnteroBiotix Closes 27M Financing Round

EnteroBiotix: EnteroBiotix raises 27m for drugs development

EnteroBiotix: Gut health firm EnteroBiotix secures 27m funding

EnteroBiotix: EnteroBiotix Initiates Phase 2 Study of EBX-102-02 in Patients with Irritable Bowel Syndrome (IBS)

EnteroBiotix: EnteroBiotix strengthens its executive team, appoints Dr James Barnes as COO and Chris Lea as CFO

EnteroBiotix: Scottish biotech firm EnteroBiotix announces new executive chairman

EnteroBiotix: EnteroBiotix begins phase 2 study of candidate drug EBX-102